Introduction
Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus associated with end-stage renal disease requiring renal replacement therapy. A major contributor to development and progression of DN is glycaemic control as shown by major diabetes studies 1, 2 . Other modifiable factors for DN include hypertension, obesity, smoking, and dyslipidaemia 3 . There is encouraging evidence suggesting that timely and long-term tight glycaemic control effectively delays the onset and slows the progression of DN in both type 1 and type 2 diabetes 4, 5 .
The diagnosis of DN is usually made through biochemical analyses of urine and
blood. An early manifestation is persistent microalbuminuria. Estimated glomerular filtration rate (eGFR) declines prior to more severe macroalbuminuria in type 2 diabetes (T2D); hence a combination of eGFR and albuminuria can be used to stage and monitor patients 6, 7 . While diabetes is the major cause of renal disease in patients with diabetes, in about a third of patients, renal dysfunction is due to other causes (non-diabetic renal disease; NDRD) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . In the NDRD group, the treatment of renal disease may require a different strategy. A renal biopsy is helpful in determining the underlying pathophysiology in NDRD.
The selection criteria for renal biopsy in diabetic patients are not well established.
In type 1 diabetes, the presence of proteinuria with short diabetes duration and/or rapidly declining renal function, especially in the absence of diabetic retinopathy, have been suggested as a signal for the need for renal biopsy 18 . In T2D, the
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6 criteria are less clear since dysglycaemia is present for many years prior to diagnosis. Commonly, proteinuria > 1 g/24 hours, renal involvement without diabetic retinopathy, or unexplained haematuria have been used as indicators for renal biopsy 19 . Identification of novel predictors of renal disease will improve the current selection criteria for renal biopsy and facilitate early detection of NDRD in T2D. Early diagnosis and appropriate treatment may help slow progression to end stage renal disease. In this study, we sought to investigate the prevalence, spectrum, and predictors of biopsy-proven NDRD in adults with T2D.
Subjects, Material and Methods
This was a retrospective observational study of T2D patients who underwent renal biopsies over 10 years in our centre. As this was an audit of retrospective data, the local research ethics committee felt that no formal ethics approval was required.
Fifty-one native renal biopsies obtained from 51 adults with a documented diagnosis of T2D, referred to our centre between 2002 and 2012, were analysed.
In our centre, as a policy, DN is diagnosed on clinical grounds and kidney biopsies are only carried out if there are atypical clinical features. Indications for biopsy, in this cohort, included nephrotic range proteinuria (> 3 g/24 hours), significant microscopic haematuria (≥ ++), or rapidly declining renal function. Renal biopsy specimens were examined by light microscopy, direct immunofluorescence, and electron microscopy, where indicated.
The biopsy report, biochemical results, and clinical information at the time of renal biopsy and follow-up were studied. Glomerular filtration rate estimates were calculated using the 4- The primary outcome measure was the prevalence and nature of histologicallyproven NDRD. The secondary outcome measures included predictors of NDRD vs.
DN and the risk factors for adverse renal outcome. Adverse renal outcomes included reaching end stage renal disease requiring renal replacement therapy or chronic kidney disease (CKD) leading to death, or a composite of the two.
Statistical Analyses
The Shapiro-Wilk test was applied to assess normality of data distribution.
Continuous variables with normal distribution are presented as means ± standard deviation (SD) and compared using the Student's t test. Continuous variables with non-normal distribution are presented as medians and interquartile ranges (IQR) and compared using the Wilcoxon rank-sum test or the Wilcoxon-matched pairs signed-ranks test. The chi-square test was applied to examine patterns between A C C E P T E D M A N U S C R I P T 
Results

Sample Characteristics and Renal Biopsy Findings
The entire cohort of renal biopsy patients (N=51) was predominantly male (64.7%), oxalate nephropathy 1 (2.9%), myeloma cast nephropathy 1 (2.9%), fibrillary glomerulonephritis 1 (2.9%), and collagenofibrotic glomerulopathy 1 (2.9%). In more than 50% of NDRD, histology prompted alteration in therapeutic management. Table 1 shows characteristics of the two subgroups based on renal biopsy findings.
The patients with NDRD had better glycaemic control 12 months before biopsy (N=32), a smaller decrease in HbA1c during the year before biopsy (N=31; Figure
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1A, Figure 1B) , and a lower rate of diabetic retinopathy than those with isolated DN. There was a trend towards more South-Asians in the DN subgroup. We did not find any difference in eGFR prior to biopsy, at the time of biopsy, and 12 months after biopsy between the two subgroups. Following the therapeutic adjustments based on renal biopsy findings, the patients with NDRD had significantly greater improvement in eGFR 12 months after biopsy (N=38) than patients with isolated DN (Table 1) . Similar numbers received RAAS blockade therapy in the two subgroups. There were no differences in duration of T2D (N=45) and in pharmacological treatment of diabetes (N=47; Table 1 ).
By the end of 2012, overall mortality was 29.4% with no difference between the subgroups. There was no difference in number of patients requiring renal replacement therapy. However, a composite adverse renal outcome (reaching end stage renal disease requiring renal replacement therapy + CKD leading to death; N=48) was higher in isolated DN subgroup (Table 1) . Table 2 presents the results of a univariate exact logistic regression analysis for unadjusted (crude) associations between NDRD and independent variables with odds ratios (OR), 95% confidence intervals (95% CI), and P-values. For subjects with diabetic retinopathy, the expected log odds of having NDRD decreased by 3.39, and the odds for NDRD declined by 97% (P<0.001). The unadjusted OR of the association between NDRD and HbA1c 12 months before biopsy was 0.60; for 12 months before biopsy, ranging from an approximately 85% probability of having NDRD in patients with a relatively low preceding HbA1c to a < 50% probability in patients with HbA1c of > 8.5% (69 mmol/mol). Of importance, the patients who experienced deterioration in HbA1c during the year prior to biopsy had at least 63% probability of having NDRD (Figure 2 , plus symbols). The HbA1c 12 months before biopsy in these patients was < 8% (64 mmol/mol).
Predictors of Renal Disease and Risk Factors for Adverse Renal Outcomes
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To further define the importance of HbA1c in predicting the NDRD, we performed receiver operating characteristic (ROC) curve analysis of three HbA1c-based
predictive models for NDRD (Figure 3) . In the first model, the HbA1c 12 months before biopsy was used. The cut point of the HbA1c 12 months before biopsy of ≥ 6.2% (44 mmol/mol) was the best predictor of NDRD with 100% sensitivity.
However, the 17% specificity reflected high rate (83%) of false positives (area under the curve AUC, 0.29; 95% CI, 0.07 to 0.51). In the second model, we measured predictive accuracy of the ΔHbA1c during the year prior to biopsy. The 
Discussion
There were three major findings in the present study First, renal biopsies with histological confirmation of renal involvement revealed a considerably high prevalence of NDRD in a cohort of T2D patients with significant dipstick haematuria, nephrotic range proteinuria, and/or rapidly declining renal function.
Second, this study confirmed the previously recognized associations between poor
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13 long-term glucose control and presence of diabetic retinopathy and DN in T2D 2 .
Third, besides the previously identified predictors of NDRD that include new onset nephrotic range proteinuria, shorter duration of diabetes, and the absence of diabetic retinopathy [21] [22] [23] , this is the first study to demonstrate that in T2D, the HbA1c 12 months before biopsy and the absolute change in HbA1c during the year before biopsy predict the type of renal disease. This study also shows that those with biopsy-proven NDRD have a better composite outcome of end stage renal disease and death.
Our finding of high prevalence of NDRD in T2D is consistent with observations made by others [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . These studies showed a variable prevalence of NDRD of 18-78%. This is attributed to selection criteria for renal biopsy and to the geographical and ethnic differences in the incidence of various NDRD. The finding of high prevalence of NDRD in this cohort of T2D patients with renal impairment and atypical features has important clinical implications; at least 50% of patients had NDRD that was treatable with steroids and immunosuppressive agents. The therapeutic adjustments based on histology and resultant modification of course of NDRD may explain the improvement in eGFR and the better composite adverse renal outcome in the NDRD subgroup. By contrast, there is no specific treatment for isolated DN 3, 6, 7 . Early and accurate diagnosis of NDRD is important for diabetic patients since treatment and prognosis may vary according to the underlying cause.
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Several recent cross-sectional and longitudinal studies have reported associations between HbA1c and kidney function in T2D with mixed results [24] [25] [26] [27] [28] [29] . Lee and colleagues 24 demonstrated a negative effect of preceding HbA1c (recorded 1 year before) on eGFR in T2D patients with CKD stages 3 and 4. In our study, a trend towards the positive association between the HbA1c 12 months before biopsy and eGFR was observed in the subgroup with isolated DN (r=0.56; P=0.058; N=12).
There was no association between the preceding HbA1c and eGFR even after the patients were grouped according to CKD stages. Of importance, our results show that both the HbA1c 12 months before biopsy and the absolute change in HbA1c during the year before biopsy differ between patients with isolated DN and NDRD with similarly decreased eGFR at the time of renal biopsy. Our study is consistent with previous observations that annual variation in HbA1c could predict DN in patients with T2D and that long-term variability of HbA1c predicts microalbuminuria 26, 27 and development/progression of renal and cardiovascular complications of T2D 28, 29 .
The ROC curve analysis of the three proposed HbA1c-based predictive models showed that although both the HbA1c 12 months before biopsy and its change during the year before biopsy predicted type of renal disease, the model based on the interaction between the two variables (INTHbA1c) had the best predictive accuracy for NDRD. Since different predictors may be sensitive to different aspects of renal diseases, this "new" predictor may improve the overall predictive capability of the HbA1c-based models. proposed HbA1c-based predictive models for NDRD with a view to refining the current selection criteria for renal biopsy in T2D patients, and identify patients that will benefit from specific therapeutic interventions that will reduce adverse renal outcomes.
Acknowledgements: MP has received grant/research support from Slovakian
Diabetes Association/Lilly Diabetes Clinical Research Initiative. AM, GL, ST and ID declare that they have no competing interests. 1-Specificity
A C C E P T E D M A N U S C R I P T
Tables
